saltar al contenido
United States
Canada
Australia
United Kingdom
India
Morocco
South Africa
China
Hong Kong SAR China
Indonesia
Malaysia
Philippines
Saudi Arabia
Singapore
South Korea
Thailand
United Arab Emirates
Austria
Denmark
Estonia
Germany
Hungary
Ireland
Lithuania
Malta
Netherlands
Norway
Spain
Switzerland
Sweden
New Zealand
Clinical Studies
Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomized double-blinded placebo-controlled trial
Introduction:Tocotrienols (TT) have been shown to benefit bone health in ovariectomized animals, a model of postmenopausal women. The purpose of this study was to evaluate the effect of 12-week TT supplementation on bone markers (serum bone-specific alkaline phosphatase (BALP), urine N-terminal telopeptide (NTX), serum soluble receptor activator of nuclear factor-kappaB ligand (sRANKL), and serum osteoprotegerin (OPG)), urine calcium, and an oxidative stress biomarker (8-hydroxy-2'-deoxyguanosine (8-OHdG)) in postmenopausal women with osteopenia.
Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease
Introduction:Non-alcoholic fatty liver disease (NAFLD) represents a clinico-histopathological spectrum of liver disorders characterized by histological features resembling alcoholic liver disease. However, by definition, NAFLD occurs in patients with little or no history of alcohol intake.
Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial
Introduction:The aim of this study was to examine the effects of delta-tocotrienol (δ-tocotrienol) supplementation on biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).
Delta tocotrienol in recurrent ovarian cancer. A phase II trial
Introduction:Delta tocotrienol has anti-neoplastic activity as demonstrated in several in-vitro and in-vivo investigations. The effect relies on inhibition of different pathways. It also has antiangiogenic activity, and an additive effect to bevacizumab may be expected.
Effects of delta-tocotrienol supplementation on Glycemic Control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: A randomized control trial
Introduction:The study aimed to ascertain the effects of delta-tocotrienol (δT3) supplementation on glycemic control, oxidative stress, inflammation and related micro-ribonucleic acid (miRNA) expression in patients with type 2 diabetes mellitus (T2DM). Total 110 patients of T2DM on oral hypoglycemic agents, were randomly divided into tocotrienol and placebo groups and given 250 mg δT3 or cellulose soft gel capsule once daily respectively for 24 weeks.
Effects of delta-tocotrienol supplementation on glycaemic control in individuals with prediabetes: A randomized controlled study
Introduction:To study the effects of delta-tocotrienol on glycaemic control parameters in individuals with pre-diabetes.
Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial
Introduction:The first human study to compare the efficacy of δT3 with αTF in the treatment of patients with NAFLD. δT3 exerted equally beneficial effects as of αTF in improving hepatic steatosis, insulin resistance and oxidative stress. δT3 was more potent than αTF in improving body weight, inflammation and hepatocyte apoptosis.